Agios Pharmaceutical shares tank amid safety concerns about drug
Agios Pharmaceuticals | December 05, 2016
Shares of Agios Pharmaceutical shed 12 percent Monday amid concern about the safety of one of the molecules in its drug to treat pyruvate kinase deficiency, a rare, genetic anemia. The company reported that one patient saw a serious adverse event after the data collection cut-off. This patient experienced drug-related cholestatic hepatitis after a 300 mg dose. Agios said it is examining this event further…